全身性エリテマトーデス治療の世界市場レポート 2025年

全身性エリテマトーデス治療の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.6％で51億9,000万米ドルに成長します。予測期間の成長は、ループス治療におけるバイオシミラーの登場、デジタルヘルスソリューションの統合、補完・代替医療への注目、免疫調節療法の革新、患者擁護・支援組織などに起因すると考えられます。予測期間における世界の動向には、コンビナトリアル療法、個別化医療アプローチ、全身性エリテマトーデス治療におけるバイオシミラー、疾患管理における遠隔医療、患者向け教育イニシアチブ、ループス研究のための世界的な協力体制などが含まれます。

自己免疫疾患の有病率の増加は、今後の全身性エリテマトーデス治療市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って身体自身の組織を攻撃することを特徴とします。これは、免疫系が身体の一部を異物として認識し、健康な細胞を標的とする自己抗体として知られるタンパク質の放出につながることで発生します。全身性エリテマトーデスは、免疫系が様々な組織を攻撃し、関節、皮膚、脳、肺、腎臓、血管などの臓器に広範な炎症と損傷をもたらす特異的な自己免疫疾患です。例えば、2023年5月、英国の研究機関であるオックスフォード大学は、自己免疫疾患が世界人口の10％に影響を与え、女性の13％、男性の7％が罹患していると報告しました。したがって、自己免疫疾患の発生率の上昇が全身性エリテマトーデス治療市場の成長を後押ししています。

ヘルスケア支出の増加は、今後の全身性エリテマトーデス治療市場の成長を促進すると予想されます。ヘルスケア支出は、特定のヘルスケアシステムや経済圏において、ヘルスケアサービス、商品、関連活動に費やされる総額のことです。ヘルスケア支出の増加は、研究開発を支援し、革新的な治療法へのアクセスを向上させ、より広範な臨床試験や研究を可能にし、全体として患者ケアと転帰を改善することで、全身性エリテマトーデス治療のより強固でダイナミックなエコシステムを促進します。例えば、2023年5月、英国の政府部門である国家統計局の報告書によると、英国のヘルスケア支出は2022～2023年にかけて5.6％増加しました。これに対し2022年の成長率は0.9%でした。また英国のヘルスケア支出は、2023年には約3,176億3,000万米ドル（2,920億英ポンド）に達しました。したがって、ヘルスケア支出の増加が全身性エリテマトーデス治療市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の全身性エリテマトーデス治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の全身性エリテマトーデス治療市場：成長率分析
• 世界の全身性エリテマトーデス治療市場の実績：規模と成長、2019～2024年
• 世界の全身性エリテマトーデス治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の全身性エリテマトーデス治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の全身性エリテマトーデス治療市場：薬物別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗マラリア薬
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 免疫抑制薬
• 世界の全身性エリテマトーデス治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 経口
• 静脈内
• 世界の全身性エリテマトーデス治療市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン販売
• 世界の全身性エリテマトーデス治療市場：抗マラリア薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヒドロキシクロロキン
• クロロキン
• 世界の全身性エリテマトーデス治療市場：非ステロイド性抗炎症薬（NSAID）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イブプロフェン
• ナプロキセン
• アスピリン
• 世界の全身性エリテマトーデス治療市場：コルチコステロイドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プレドニゾン
• メチルプレドニゾロン
• 世界の全身性エリテマトーデス治療市場：免疫抑制薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アザチオプリン
• ミコフェノール酸モフェチル
• シクロホスファミド
• ベリムマブ

第7章 地域別・国別分析

• 世界の全身性エリテマトーデス治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の全身性エリテマトーデス治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 全身性エリテマトーデス治療市場：競合情勢
• 全身性エリテマトーデス治療市場：企業プロファイル
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Aurinia Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company Inc.
• F. Hoffmann-La Roche Ltd.
• ImmuPharma plc
• Sanofi SA
• Eli Lilly and Company
• Johnson & Johnson Services Inc.
• Roche Holding AG
• Bayer AG
• Novartis International AG
• Viatris Inc.
• Horizon Therapeutics plc
• EMD Serono Inc.
• Hoth Therapeutics Inc.
• Kyowa Kirin Co. Ltd.
• AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 全身性エリテマトーデス治療市場2029年：新たな機会を提供する国
• 全身性エリテマトーデス治療市場2029年：新たな機会を提供するセグメント
• 全身性エリテマトーデス治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Systemic lupus erythematosus (SLE) is an autoimmune disease that prompts the immune system to attack the body's own tissues, leading to widespread inflammation and damage in multiple organs including the joints, skin, brain, lungs, kidneys, and blood vessels. While it cannot be cured, medical treatments and lifestyle adjustments can help manage the condition. The treatment primarily involves the use of drugs that suppress the overactive immune response.

The main categories of drugs used in treating systemic lupus erythematosus include antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive drugs. Antimalarial medications such as hydroxychloroquine (Plaquenil), chloroquine (Aralen), and quinacrine (Atabrine) have shown efficacy in managing lupus symptoms. These drugs are administered through various routes including subcutaneous, oral, and intravenous methods. Treatments for SLE are available through diverse channels including hospital pharmacies, retail pharmacies, and online sales.

The systemic lupus erythematosus treatment market research report is one of a series of new reports from The Business Research Company that provides systemic lupus erythematosus treatment market statistics, including systemic lupus erythematosus treatment industry global market size, regional shares, competitors with a systemic lupus erythematosus treatment market share, detailed systemic lupus erythematosus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the systemic lupus erythematosus treatment industry. This systemic lupus erythematosus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $3.03 billion in 2024 to $3.35 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in biologics and targeted therapies, increased understanding of disease mechanisms, clinical trials and research initiatives, government initiatives for rare disease treatment, increased awareness and diagnosis of lupus.

The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $5.19 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to emergence of biosimilars for lupus treatment, integration of digital health solutions, focus on complementary and alternative medicine, innovations in immunomodulatory therapies, patient advocacy and support organizations. Major trends in the forecast period include combinatorial therapies, personalized medicine approaches, biosimilars in sle treatment, telemedicine in sle management, educational initiatives for patients, global collaborations for lupus research.

The increasing prevalence of autoimmune disorders is anticipated to drive the growth of the systemic lupus erythematosus treatment market in the future. An autoimmune disease is characterized by the immune system mistakenly attacking the body's own tissues. This occurs when the immune system identifies parts of the body as foreign, leading to the release of proteins known as autoantibodies that target healthy cells. Systemic lupus erythematosus is a specific autoimmune condition where the immune system attacks various tissues, resulting in widespread inflammation and damage to affected organs, including the joints, skin, brain, lungs, kidneys, and blood vessels. For example, in May 2023, the University of Oxford, a UK-based research institution, reported that autoimmune disorders impact 10% of the global population, affecting 13% of women and 7% of men. Therefore, the rising incidence of autoimmune disorders is fueling the growth of the systemic lupus erythematosus treatment market.

The rise in healthcare expenditure is expected to drive the growth of the systemic lupus erythematosus treatment market in the future. Healthcare expenditure encompasses the total amount spent on healthcare services, goods, and related activities within a specific healthcare system or economy over a defined timeframe. Increased healthcare spending fosters a more robust and dynamic ecosystem for systemic lupus erythematosus treatment by supporting research and development, enhancing access to innovative therapies, enabling more extensive clinical trials and studies, and overall improving patient care and outcomes. For instance, in May 2023, a report from the Office for National Statistics, a UK government department, noted that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. The UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the systemic lupus erythematosus treatment market.

Leading companies in the Systemic Lupus Erythematosus (SLE) treatment market are increasingly channeling investments into the research and development of innovative therapies and biologics to enhance patient outcomes and address the unmet needs of individuals affected by this complex autoimmune disease. The pursuit of innovative therapies represents a vital frontier in improving treatment options and the quality of life for patients facing difficult health challenges. For example, in August 2024, Noxopharm Limited, an Australia-based biotech firm, announced the commencement of its first-in-human clinical trial for its drug candidate, SOF-SKN, which targets autoimmune diseases, particularly cutaneous lupus erythematosus (CLE). SOF-SKN is a first-in-class oligonucleotide TLR7/8 antagonist designed to tackle the root causes of CLE rather than simply managing symptoms. This strategy marks a significant shift in the treatment paradigm for this autoimmune skin condition, which currently has no cure and often necessitates ongoing symptom management.

Companies operating in the systemic lupus erythematosus (SLE) treatment market are concentrating on investing in advanced therapies, such as monoclonal antibodies and oral immunomodulators, to enhance treatment efficacy and meet the unmet needs of patients suffering from this chronic autoimmune disease. These innovative treatments encompass biologics, small molecules, and other therapeutic modalities that specifically target pathways involved in immune dysregulation. For instance, in March 2023, NImmune Biopharma, a US-based biopharmaceutical company, introduced NIM-1324. This therapeutic candidate is designed to address the immune dysregulation associated with Systemic Lupus Erythematosus (SLE), aiming to provide a more effective and targeted therapy for patients. NIM-1324 is a Phase-2-ready oral treatment that targets the LANCL2 pathway and enhances immunoregulatory functions, striving to deliver a safer and more effective option for Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The development of NIM-1324 is part of NImmune's broader strategy to utilize advanced computational modeling and bioinformatics to streamline drug discovery and development.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for $1.0 billion. This acquisition aims to bolster AstraZeneca's pipeline of innovative therapies for cancer and autoimmune diseases, including systemic lupus erythematosus and its novel FasTCAR-enabled CAR-T therapy, GC012F. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical firm that has developed cell therapies for cancer and autoimmune diseases.

Major companies operating in the systemic lupus erythematosus treatment market include GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., AstraZeneca plc, Bristol-Myers Squibb Company Inc., F. Hoffmann-La Roche Ltd., ImmuPharma plc, Sanofi SA, Eli Lilly and Company, Johnson & Johnson Services Inc., Roche Holding AG, Bayer AG, Novartis International AG, Viatris Inc., Horizon Therapeutics plc, EMD Serono Inc., Hoth Therapeutics Inc., Kyowa Kirin Co. Ltd., AbbVie Inc., Takeda Pharmaceutical Company Limited

North America was the largest region in the systemic lupus erythematosus treatment market in 2024. The regions covered in the systemic lupus erythematosus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the systemic lupus erythematosus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The systemic lupus erythematosus treatment market consists of sales of systemic lupus erythematosus drugs including antimalarial drugs such as chloroquine, and hydrochlorquine, cytotoxic, and immunosuppressive drugs such as cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, biologics such as b-cell modulators, t-cell modulators, pro-inflammatory, as well as cytokine inhibitors, corticosteroids such as prednisone, hydrocortisone, dexamethasone, and other drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Systemic Lupus Erythematosus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on systemic lupus erythematosus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for systemic lupus erythematosus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The systemic lupus erythematosus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Antimalarial Drugs; Non-Steroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Immunosuppressive Drugs
• 2) By Route Of Administration: Sub-Cutaneous; Oral; Intravenous
• 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Sales
• Subsegments:
• 1) By Antimalarial Drugs: Hydroxychloroquine; Chloroquine
• 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin
• 3) By Corticosteroids: Prednisone; Methylprednisolone
• 4) By Immunosuppressive Drugs: Azathioprine; Mycophenolate Mofetil; Cyclophosphamide; Belimumab
• Companies Mentioned: GlaxoSmithKline plc; Aurinia Pharmaceuticals Inc.; Pfizer Inc.; Merck & Co Inc.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Systemic Lupus Erythematosus Treatment Market Characteristics

3. Systemic Lupus Erythematosus Treatment Market Trends And Strategies

4. Systemic Lupus Erythematosus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Systemic Lupus Erythematosus Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Systemic Lupus Erythematosus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Systemic Lupus Erythematosus Treatment Market Growth Rate Analysis
• 5.4. Global Systemic Lupus Erythematosus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Systemic Lupus Erythematosus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Systemic Lupus Erythematosus Treatment Total Addressable Market (TAM)

6. Systemic Lupus Erythematosus Treatment Market Segmentation

• 6.1. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimalarial Drugs
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Corticosteroids
• Immunosuppressive Drugs
• 6.2. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sub-Cutaneous
• Oral
• Intravenous
• 6.3. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Sales
• 6.4. Global Systemic Lupus Erythematosus Treatment Market, Sub-Segmentation Of Antimalarial Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydroxychloroquine
• Chloroquine
• 6.5. Global Systemic Lupus Erythematosus Treatment Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Aspirin
• 6.6. Global Systemic Lupus Erythematosus Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• 6.7. Global Systemic Lupus Erythematosus Treatment Market, Sub-Segmentation Of Immunosuppressive Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azathioprine
• Mycophenolate Mofetil
• Cyclophosphamide
• Belimumab

7. Systemic Lupus Erythematosus Treatment Market Regional And Country Analysis

• 7.1. Global Systemic Lupus Erythematosus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Systemic Lupus Erythematosus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Systemic Lupus Erythematosus Treatment Market

• 8.1. Asia-Pacific Systemic Lupus Erythematosus Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Systemic Lupus Erythematosus Treatment Market

• 9.1. China Systemic Lupus Erythematosus Treatment Market Overview
• 9.2. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Systemic Lupus Erythematosus Treatment Market

• 10.1. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Systemic Lupus Erythematosus Treatment Market

• 11.1. Japan Systemic Lupus Erythematosus Treatment Market Overview
• 11.2. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Systemic Lupus Erythematosus Treatment Market

• 12.1. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Systemic Lupus Erythematosus Treatment Market

• 13.1. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Systemic Lupus Erythematosus Treatment Market

• 14.1. South Korea Systemic Lupus Erythematosus Treatment Market Overview
• 14.2. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Systemic Lupus Erythematosus Treatment Market

• 15.1. Western Europe Systemic Lupus Erythematosus Treatment Market Overview
• 15.2. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Systemic Lupus Erythematosus Treatment Market

• 16.1. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Systemic Lupus Erythematosus Treatment Market

• 17.1. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Systemic Lupus Erythematosus Treatment Market

• 18.1. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Systemic Lupus Erythematosus Treatment Market

• 19.1. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Systemic Lupus Erythematosus Treatment Market

• 20.1. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Systemic Lupus Erythematosus Treatment Market

• 21.1. Eastern Europe Systemic Lupus Erythematosus Treatment Market Overview
• 21.2. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Systemic Lupus Erythematosus Treatment Market

• 22.1. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Systemic Lupus Erythematosus Treatment Market

• 23.1. North America Systemic Lupus Erythematosus Treatment Market Overview
• 23.2. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Systemic Lupus Erythematosus Treatment Market

• 24.1. USA Systemic Lupus Erythematosus Treatment Market Overview
• 24.2. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Systemic Lupus Erythematosus Treatment Market

• 25.1. Canada Systemic Lupus Erythematosus Treatment Market Overview
• 25.2. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Systemic Lupus Erythematosus Treatment Market

• 26.1. South America Systemic Lupus Erythematosus Treatment Market Overview
• 26.2. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Systemic Lupus Erythematosus Treatment Market

• 27.1. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Systemic Lupus Erythematosus Treatment Market

• 28.1. Middle East Systemic Lupus Erythematosus Treatment Market Overview
• 28.2. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Systemic Lupus Erythematosus Treatment Market

• 29.1. Africa Systemic Lupus Erythematosus Treatment Market Overview
• 29.2. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Systemic Lupus Erythematosus Treatment Market Competitive Landscape And Company Profiles

• 30.1. Systemic Lupus Erythematosus Treatment Market Competitive Landscape
• 30.2. Systemic Lupus Erythematosus Treatment Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Aurinia Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Systemic Lupus Erythematosus Treatment Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company Inc.
• 31.2. F. Hoffmann-La Roche Ltd.
• 31.3. ImmuPharma plc
• 31.4. Sanofi SA
• 31.5. Eli Lilly and Company
• 31.6. Johnson & Johnson Services Inc.
• 31.7. Roche Holding AG
• 31.8. Bayer AG
• 31.9. Novartis International AG
• 31.10. Viatris Inc.
• 31.11. Horizon Therapeutics plc
• 31.12. EMD Serono Inc.
• 31.13. Hoth Therapeutics Inc.
• 31.14. Kyowa Kirin Co. Ltd.
• 31.15. AbbVie Inc.

32. Global Systemic Lupus Erythematosus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Systemic Lupus Erythematosus Treatment Market

34. Recent Developments In The Systemic Lupus Erythematosus Treatment Market

35. Systemic Lupus Erythematosus Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Systemic Lupus Erythematosus Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Systemic Lupus Erythematosus Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Systemic Lupus Erythematosus Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer